Repligen Completes Acquisition of BioLife Solutions

approvedCryoStor®Positive

AI Analysis

Summary

Repligen Corporation has completed its acquisition of BioLife Solutions, Inc., combining complementary bioprocessing portfolios to expand presence in the cell and gene therapy market. BioLife stockholders received $11.25 per share in cash plus 0.1442 Repligen shares.

Outcome Details

Repligen completed acquisition of BioLife Solutions. BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock.

Importance:7/10

Sentiment:

0.70

M&Acell therapybioprocessingacquisition completedconsumables

Related Companies

$RGEN $BLFS

Read the original article

Published by GlobeNewswire Pharma on October 6, 2026 1:05 PM

Read Original